In individuals with cystic fibrosis (CF), colonization with methicillin-resistant Staphylococcus aureus (MRSA) was reported to be associated with a deterioration of pulmonary disease as reflected by an accelerated decline in lung function. Thus, an early eradication of MRSA could be beneficial in these patients. Here, we report on an intensified MRSA eradication protocol. Since 2012 a protocol for the eradication of newly acquired MRSA has been used in our CF Clinic, combining oral rifampicin and fusidic acid, inhaled vancomycin, nasal mupirocin, local antiseptic treatment and hygienic directives all of which are applied for only 7 days during an inpatient hospital stay. Since 2012 seven patients (3 male, 4 female; age range 4 to 30 years) newly acquired MRSA. In 6 of the 7 patients (86%) successful eradication of MRSA was achieved upon first treatment using the protocol described above. In one patient a second course of treatment was performed which, however, also failed to eliminate the colonizing MRSA. Our protocol led to an eradication rate of 86%. The impact of each individual component of the protocol remains to be determined.
Background: Human metapneumovirus (hMPV) is a significant respiratory pathogen in infants and young children. Although most infections present as nonsevere cases in outpatient settings, severe courses can lead to hospitalization. Few potential risk factors for hospitalization have already been identified, but studies comparing the clinical presentation of children with hMPV in inpatient versus outpatient settings are lacking. Methods: This retrospective analysis used data from the Pediatric Airway Pathogen Incidence study, a multicenter surveillance study of lower respiratory tract infections, conducted in Germany during winter seasons 2021/22 and 2022/23 (weeks 40–17 each season). We compared 102 hospitalized and 114 outpatient pediatric cases with laboratory-confirmed hMPV infection after excluding coinfections with respiratory syncytial virus. Detailed clinical and demographic data were collected. Results: Hospitalized patients were significantly younger (median age 9 vs. 14 months, P = 0.003) than outpatients. Prematurity was notably higher in severe cases (25% vs. 6.2%, P < 0.001), and extreme prematurity (gestational age <28 weeks) was present only in hospitalized patients. Hospitalized cases were independently associated with a history of recurrent wheezing, but not with neonatal invasive and noninvasive respiratory support, inhalative steroids and bronchopulmonary dysplasia. On clinical examination, hospitalized children more often exhibited wheezing, crackles, tachypnea, hypoxemia and reduced fluid intake. Hypoxemia in hMPV was independently associated with gestational age at birth, but not with age at diagnosis. Conclusion: The clinical presentation of hMPV in hospitalized young children differed from that observed in outpatient settings. We identified multiple factors that were independently associated with hMPV-related hospitalization.
1 March 2026 in International Journal of Infectious Diseases
Respiratory syncytial virus (RSV) is a major cause of morbidity globally, with most cases managed in outpatient settings. However, data characterizing the disease burden of non-severe RSV infections remain limited. The prospective, multicenter pediatric airway pathogen incidence (PAPI) study enrolled 1450 children aged ≤24 months presenting with lower respiratory tract infections (LRTI) in outpatient settings between October 2021 and April 2023. Clinical data, detected pathogens via multiplex polymerase chain reaction, and follow-up data were collected. Among enrolled patients 19.7% tested positive for RSV. RSV-positive patients (RSV+) exhibited distinct clinical characteristics, including significantly higher proportions of wheezing, crackles, and tachypnoea than RSV-negative patients. Notably, we identified a previously unreported association between RSV infection and atopic conditions, with RSV+ patients demonstrating higher proportions of atopic eczema (odds ratio 1.65 [95% CI: 1.05-2.61]). 96.5% of all RSV+ patients received pharmacotherapy, predominantly beta-sympathomimetics, inhaled saline, and antipyretics. The mean recovery time was 12 days. In the outpatient setting, RSV infections during the first 2 years of life present with distinct clinical features and increased morbidity compared with other respiratory pathogens. The association with atopic conditions warrants further investigation. These findings characterize the considerable RSV burden in primary care before the implementation of immunization measures. DRKS00026155.